{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T12:36:57Z","timestamp":1777379817633,"version":"3.51.4"},"reference-count":24,"publisher":"SAGE Publications","issue":"10","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["AIDS Research and Human Retroviruses"],"published-print":{"date-parts":[[2021,10]]},"abstract":"<jats:p>Data on two-drug regimens (2DRs) have shown high efficacy and tolerability in treatment-naive and treatment-experienced HIV-1 patients. Current guidelines recommend 2DRs as alternative to three-drug regimens (3DRs) to reduce long-term drug exposure and costs. Nevertheless, real-world experience with 2DR is limited. This study assessed the use of 2DR in routine clinical practice in a tertiary hospital. A retrospective, observational, descriptive study was performed on the use of dual therapy in adult HIV-1 patients. Individuals on antiretroviral treatment (ART) with dolutegravir plus lamivudine or dolutegravir plus rilpivirine who started 2DR between November 1, 2018, and April 30, 2019, were eligible for our study. Follow-up period was 48 weeks. Overall, 112 patients started 2DR; median age was 51 years and 88.4% were men. Most patients (97.3%) were treatment experienced before dual therapy, with 9.6\u2009\u00b1\u20098.0 years of prior ART on average. Around 96.4% of patients were virologically suppressed before 2DR. Most common reasons to start dual therapy were treatment simplification (49.5%), avoidance of long-term toxicities (21.1%), and intolerance to previous ART (18.3%). The main regimen used in dual therapy was dolutegravir plus lamivudine (98.2%). Only eight patients discontinued dual therapy; the main reason for discontinuation was toxicity. All patients who did not discontinue 2DR were virologically suppressed at week 48. ART simplification saved \u20ac130,117.58 during the study period. In our cohort, dual therapy was mainly used for virologically suppressed patients, before availability of the single-tablet 2DR. Switching to a 2DR may be a key option for treatment simplification and avoidance of long-term toxicities. Furthermore, 2DR could provide a more cost-effective alternative to 3DR.<\/jats:p>","DOI":"10.1089\/aid.2021.0041","type":"journal-article","created":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:59:04Z","timestamp":1630457944000},"page":"761-767","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":5,"title":["Real-World Experience with Two-Drug Regimens in HIV-1-Infected Patients Beyond the Indication of Clinical Trials: 48 Weeks' Results"],"prefix":"10.1177","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1439-2351","authenticated-orcid":false,"given":"Ana","family":"Aranc\u00f3n Pardo","sequence":"first","affiliation":[{"name":"Pharmacy Department, La Paz University Hospital-IdiPAZ, Madrid, Spain."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Moreno Palomino","sequence":"additional","affiliation":[{"name":"Pharmacy Department, La Paz University Hospital-IdiPAZ, Madrid, Spain."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inmaculada","family":"Jim\u00e9nez-N\u00e1cher","sequence":"additional","affiliation":[{"name":"Pharmacy Department, La Paz University Hospital-IdiPAZ, Madrid, Spain."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"Moreno","sequence":"additional","affiliation":[{"name":"Pharmacy Department, La Paz University Hospital-IdiPAZ, Madrid, Spain."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda \u00c1ngeles","family":"Gonz\u00e1lez Fern\u00e1ndez","sequence":"additional","affiliation":[{"name":"Pharmacy Department, La Paz University Hospital-IdiPAZ, Madrid, Spain."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Gonz\u00e1lez-Garc\u00eda","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Internal Medicine Department, La Paz University Hospital-IdiPAZ, Madrid, Spain."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alicia","family":"Herrero Ambrosio","sequence":"additional","affiliation":[{"name":"Pharmacy Department, La Paz University Hospital-IdiPAZ, Madrid, Spain."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2021,10,11]]},"reference":[{"key":"e_1_3_5_2_2","unstructured":"EACS Guidelines 2020 [Internet]: EACS Guidelines. Available at https:\/\/eacs.sanfordguide.com\/front-page (2021) accessed January24 2021."},{"key":"e_1_3_5_3_2","unstructured":"What's New in the Guidelines? | Adult and Adolescent ARV | ClinicalInfo [Internet]. Available at https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/adult-and-adolescent-arv\/whats-new-guidelines (2021) accessed January24 2021."},{"key":"e_1_3_5_4_2","unstructured":"Arribas JR Polo R Garc\u00eda JG Palacios R: Esteban Mart\u00ednez (GeSIDA) 2020 145. https:\/\/gesida-seimc.org\/wp-content\/uploads\/2020\/07\/TAR_GUIA_GESIDA_2020_COMPLETA_Julio.pdf accessed January16 2021."},{"key":"e_1_3_5_5_2","doi-asserted-by":"publisher","DOI":"10.4414\/smw.2001.06132"},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2019.0171"},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(15)00096-1"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(15)00097-3"},{"key":"e_1_3_5_9_2","first-page":"1163","article-title":"Treatment simplification to atazanavir\/ritonavir + lamivudine versus maintenance of atazanavir\/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients: 48week results from a randomized trial (ATLAS-M)","volume":"72","author":"Di Giambenedetto S","year":"2017","unstructured":"Di Giambenedetto S, , Fabbiani M, , Quiros Roldan E, et al.: Treatment simplification to atazanavir\/ritonavir + lamivudine versus maintenance of atazanavir\/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients: 48week results from a randomized trial (ATLAS-M). J Antimicrob Chemother, 2017; 72:1163\u20131171.","journal-title":"J Antimicrob Chemother"},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix734"},{"key":"e_1_3_5_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dky299"},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12977-017-0360-7"},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)33095-7"},{"key":"e_1_3_5_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000002449"},{"key":"e_1_3_5_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32462-0"},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000002275"},{"key":"e_1_3_5_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz1243"},{"issue":"4","key":"e_1_3_5_18_2","first-page":"2","article-title":"Two-drug vs","volume":"20","author":"Moreno S","year":"2019","unstructured":"Moreno S, , Perno CF, , Mallon PW, et al.: Two-drug vs. three-drug combinations for HIV-1: Do we have enough data to make the switch? HIV Med, 2019; 20(Suppl. 4):2\u201312.","journal-title":"three-drug combinations for HIV-1: Do we have enough data to make the switch? HIV Med"},{"key":"e_1_3_5_19_2","doi-asserted-by":"publisher","DOI":"10.4103\/picr.PICR_36_18"},{"key":"e_1_3_5_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-020-00290-w"},{"key":"e_1_3_5_21_2","doi-asserted-by":"publisher","DOI":"10.1097\/QCO.0000000000000615"},{"key":"e_1_3_5_22_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000002320"},{"key":"e_1_3_5_23_2","first-page":"5923256","article-title":"Real-world experience with dolutegravir-based two-drug regimens","volume":"2020","author":"Ward D","year":"2020","unstructured":"Ward D, , Ramgopal M, , Riedel DJ, et al.: Real-world experience with dolutegravir-based two-drug regimens. AIDS Res Treat, 2020; 2020:5923256.","journal-title":"AIDS Res Treat"},{"key":"e_1_3_5_24_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12981-020-00268-1"},{"key":"e_1_3_5_25_2","doi-asserted-by":"publisher","DOI":"10.1080\/09540121.2018.1442554"}],"container-title":["AIDS Research and Human Retroviruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/aid.2021.0041","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/aid.2021.0041","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/aid.2021.0041","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T09:15:41Z","timestamp":1777367741000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.1089\/aid.2021.0041"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":24,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["10.1089\/aid.2021.0041"],"URL":"https:\/\/doi.org\/10.1089\/aid.2021.0041","relation":{},"ISSN":["0889-2229","1931-8405"],"issn-type":[{"value":"0889-2229","type":"print"},{"value":"1931-8405","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10]]}}}